5.28
-0.06 (-1.07%)
| Previous Close | 5.34 |
| Open | 5.27 |
| Volume | 9,209 |
| Avg. Volume (3M) | 38,886 |
| Market Cap | 24,161,468 |
| Price / Sales | 3.40 |
| Price / Book | 1.46 |
| 52 Weeks Range | |
| Earnings Date | 12 May 2025 - 16 May 2025 |
| Operating Margin (TTM) | -412.44% |
| Diluted EPS (TTM) | -46.59 |
| Quarterly Revenue Growth (YOY) | -51.60% |
| Total Debt/Equity (MRQ) | 6,223.48% |
| Current Ratio (MRQ) | 11.03 |
| Operating Cash Flow (TTM) | -60.92 M |
| Levered Free Cash Flow (TTM) | -44.23 M |
| Return on Assets (TTM) | -41.10% |
| Return on Equity (TTM) | -270.01% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Cara Therapeutics, Inc. | Mixed | Mixed |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | 3.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 0.0 |
| Average | 1.00 |
|
Cara Therapeutics Inc is a development-stage biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Cara's most advanced compound, CR845, aims to treat acute pain and pruritus. This patented compound has analgesic, anti-inflammatory, and antipruritic properties that can be used for multiple therapeutic applications. Additionally, Cara's objective is to use its proprietary drug-screening technology to develop a future pipeline of first-in-class molecules with analgesic and anti-inflammatory features. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 13.07% |
| % Held by Institutions | 24.17% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |